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Abstract
Human VRK1 induces a stabilization and accumulation of p53 by specific phosphorylation in Thr18. This p53 accumulation is
reversed by its downregulation mediated by Hdm2, requiring a dephosphorylated p53 and therefore also needs the
removal of VRK1 as stabilizer. This process requires export of VRK1 to the cytosol and is inhibited by leptomycin B. We have
identified that downregulation of VRK1 protein levels requires DRAM expression, a p53-induced gene. DRAM is located in
the endosomal-lysosomal compartment. Induction of DNA damage by UV, IR, etoposide and doxorubicin stabilizes p53 and
induces DRAM expression, followed by VRK1 downregulation and a reduction in p53 Thr18 phosphorylation. DRAM
expression is induced by wild-type p53, but not by common human p53 mutants, R175H, R248W and R273H.
Overexpression of DRAM induces VRK1 downregulation and the opposite effect was observed by its knockdown. LC3 and
p62 were also downregulated, like VRK1, in response to UV-induced DNA damage. The implication of the autophagic
pathway was confirmed by its requirement for Beclin1. We propose a model with a double regulatory loop in response to
DNA damage, the accumulated p53 is removed by induction of Hdm2 and degradation in the proteasome, and the p53-
stabilizer VRK1 is eliminated by the induction of DRAM that leads to its lysosomal degradation in the autophagic pathway,
and thus permitting p53 degradation by Hdm2. This VRK1 downregulation is necessary to modulate the block in cell cycle
progression induced by p53 as part of its DNA damage response.
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Introduction
The cellular response to DNA damage is partly mediated by the
p53 tumor suppressor, which determines the response specificity
among different possibilities, such as cell cycle arrest, DNA repair,
induction of apoptosis [1,2] or autophagy [3,4]. In cells responding
to DNA damage, p53 has to be phosphorylated in its N-terminal
transactivation domain, where several residues [5] are targeted by
several kinases implicated in the response to different types of
cellular damage or stress [6]. The consequence of these
phosphorylations is to generate a transcriptionally active p53
protein, but differences in the pattern of multiphosphorylation can
condition p53 protein interactions with transcriptional cofactors,
and thus affect the specificity of the response [7,8,9]. The
phosphorylation of p53 in Thr18 is the most critical phosphor-
ylation for selective binding to transcriptional coactivators, such as
p300, or preventing binding to negative regulators, such as Hdm2
[7,8,9]. To the specificity of these cofactor interactions also
contribute phosphorylations in Ser15 or Ser20 [7,8,9]. The p53
molecule is stabilized by phosphorylation; and phosphorylated
p53, which accumulates in response to DNA damage [5], cannot
be degraded by the proteasome, because it cannot interact with
mdm2/Hdm2 [7,8,9]. In this context p53 phosphorylation in
Thr18 is the main switch from binding to mdm2 to interaction
with transcriptional cofactors [7,8,9]. Biological responses medi-
ated by p53 are a consequence of a complex network of positive
and negative autoregulatory loops [10].
VRK1 (vaccinia-related kinase-1) is a novel ser-thr kinase that
participates in cell cycle regulation [11,12]. VRK1 is expressed in
the G0 exit-G1 entry, behaving as an immediate-early gene like
MYC and FOS [13], being expressed before cyclin D1 [13], and
forming part of the CCDN1 (cyclin D1) gene transcriptional
complex [14]. VRK1 is also required for assembly of the nuclear
envelope later in mitosis [15,16], and is affected by its interaction
with Ran, a protein regulating nuclear transport [17]. VRK1
knock-down induces a block in cell cycle progression [18] before
the restriction point in G1 [13], resulting in a mitotic delay [13]. In
head and neck carcinomas the VRK1 protein level correlates with
cell proliferation markers, such as Ki67 [19]. One of the best
characterized targets of VRK1 is p53, which is specifically
phosphorylated in Thr18 [18,20] disrupting the interaction with
Hdm2, and leading to its accumulation [18]. But if p53 is
maintained in a Thr18 phosphorylated form it cannot interact
with Hdm2 [21,22], and there would be a permanent cell cycle
arrest and possibly cell death by apoptosis or autophagy. Thus a
mechanism that downregulates the level of VRK1, a stabilizer of
p53, to prevent a long-lasting p53 accumulation has been
identified, which is not mediated by ubiquitylation, and that
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VRK1 is inducible by an accumulation of p53 after a stress
response, and requires de novo transcription of a gene not yet
identified but whose product targets VRK1 to enter the lysosomal
pathway of protein degradation [23,24]. By removing VRK1, p53
can be dephosphorylated and thus become accessible to Hdm2
and subsequent degradation in the proteasome. This mechanism is
altered in lung carcinomas with p53 mutations, which have very
high levels of VRK1 [25].
Among the degradation processes regulated by p53 is
autophagy. By this process cells remove and digest endogenous
proteins, particularly those that are very stable, functioning as an
important mechanism for tissue remodeling [26] and maintaining
cellular homeostasis [27], but it can also result in a form of cell
death, thus having a dual role [28,29]. In normal cells autophagy
contributes to regulate basal levels of cytosolic and particulate
proteins [3], a process that is further activated in response to
several types of stress, including DNA damage. Autophagy is
required for recycling of proteins implicated in negative cell cycle
regulation, and can provide a survival strategy to tumor cells [26].
Recently a protein, DRAM (Damage-Regulated Autophagy
Modulator), whose expression is induced by p53, has been shown
to participate in degradation of stable proteins; DRAM ( is a novel
damage-regulated autophagy modulator) component of the cell
autophagic response [30]. Autophagy is partly regulated by p53-
induced DRAM expression [30], and since p53-induced VRK1
degradation requires entry in the endosomal-lysosomal pathway
and is mediated by an unknown gene [23], DRAM might be a
likely candidate to participate in this process, since VRK1 is also a
very stable protein [24]. In this work it has been tested the
possibility that DRAM might be implicated in the autophagic
degradation of VRK1 protein induced by p53 in the context of
DNA damage response induced by UV light.
Results
DRAM gene expression is induced in response to DNA
damage
Different types of DNA damage can induce p53 phosphoryla-
tion and its accumulation [5]. DRAM gene induction by DNA
damage and p53 accumulation was detected in RKO and Saos-2
cells [30]. Therefore, it was studied if in DNA damage responses,
DRAM activation and mainly VRK1 downregulation were also
detected in normal human WS1 fibroblasts that have a wild-type
p53. For this aim WS1 cells were treated with several types of
DNA damaging agents, such as ionizing radiation (IR) or
ultraviolet-C light (254 nm) and also doxorubicin and etoposide,
as positive controls. The dose of UV used was selected for its
maximum effect on p53 accumulation and its phosphorylation in
Thr18 (Fig. 1A). The time selected for observation was based on
the timing of activation and transcriptional responses known to be
mediated by p53 [5]. All these DNA damaging agents induced an
accumulation of endogenous p53 protein and downregulation of
VRK1 protein (Fig. 1B, top), as well as activation of DRAM gene
expression (Fig. 1B, bottom), which was determined as positive
internal control of the p53 response to DNA damage [30] in order
to detect the relative change of VRK1 with respect to DRAM in
the same cell line.
Next, it was tested if activation of endogenous DRAM gene
expression has the same p53 transcriptional requirements as those
required for VRK1 lysosomal proteolytic downregulation induced
by p53. Downregulation of VRK1 induced by p53 requires de
novo transcription of an unknown p53-induced gene, an effect that
was not induced by the most common p53 mutations in humans,
R175H, R248W and R273H [23]. For this aim, H1299 cells
(p532/2) were transfected with a wild-type p53 construct or the
three most common p53 mutants detected in human cancer. Wild-
type p53 induced DRAM gene expression in a p53 dose dependent
manner (Fig. 1C), but none of the p53 mutants was able to activate
DRAM gene expression (Fig. 1D). Thus the effect of p53 on DRAM
expression is similar to those reported for induction of VRK1
protein downregulation [23,25]. This suggested that DRAM might
be a candidate protein, or a component of the route, required to
mediate p53-dependent degradation of VRK1 in lysosomes.
DRAM downregulates VRK1 protein level
Previously it has been ruled out the implication of the ubiquitin
pathway. VRK1 is not ubiquitylated and its proteolytic p53-
induced downregulation is not mediated by mdm2 [23]. VRK1 is
also insensitive to mdm2 overexpression and it downregulation
also occurs in mdm22/2 cells [23]. VRK1 protein kinase has
been shown to be a new target of proteolytic degradation by the
lysosomal pathway in a p53-dependent manner; VRK1 degrada-
tion is inhibited by lysosomal inhibitors, such as chloroquinne and
leupeptin [23,24]. The VRK1 protein has several target sequences
for the endosomal-lysosomal pathway. There are two types of
targeting motifs for this pathway: Sequences for endosomal
targeting (End) and sequences for lysosomal-endosomal targeting
(LysEnd). VRK1 protein contains both of these motifs [24]. The
target sequences within VRK1 protein are located at 107–110,
126–129, 249–252 and 317–320 aminoacids for End sequences;
and 191–196 and 304–309 aminoacids for LysEnd target
sequences (ELM database).
Therefore, it was studied if downregulation of VRK1 requires
the participation of lysosomal DRAM protein, as a component of
its degradation route, which by its characteristics is a candidate to
mediate this effect [30]. The direct effect of DRAM protein on
VRK1 level was determined. For these experiments the lung
carcinoma H1299 (p532/2) cell line that lacks p53 was used.
This cell line was transfected with increasing levels of DRAM and
studied its effect on VRK1 protein level and on TSG101 protein,
which was used as a negative control for lack of effect on the
promoter of their common expression vector. DRAM induced a
dose dependent degradation of the VRK1 protein (Fig. 2A), but
not of the TSG101control expressed from the same type of vector
(Fig. 2B). TSG101 is an endosomal protein implicated in recycling
of plasma membrane receptors and viral entry, thus since this
protein was not affected it indicated that VRK1 and TSG101
must be in different types of endosomal vesicles [31,32]. Caveolin
a marker for a subtype of vesicles located in trans-Golgi and
plasma membrane [33] was also not affected (Fig. 2B). These data
suggested that there are two different types of endosomal vesicles,
some regulating receptor recycling and others involved in
autophagy that can be discriminated by DRAM. Also the effect
of DRAM on the closely related VRK2A and VRK2B proteins
[19,34] was determined with a similar result (Fig. S1A, B). These
results indicated that DRAM protein participates in an interme-
diate step required for VRK1 and VRK2 protein degradation by
their entry in a subtype of endosomal vesicles destined for
autophagy.
Most of the human VRK1 protein is located in the nucleus [18],
but DRAM is acting in the cytosol. This implies that VRK1, in
order to be degraded by this route, has to be transported to the
cytosol. Degradation of VRK1 might occur by elimination of the
cytosolic pool, which requires the export of nuclear VRK1
protein. VRK1 has a nuclear export signal in its C-terminal region
(residues 298–310) [20]. To test this possibility, cells were treated
with leptomycin B that blocks nuclear export [35]. Leptomycin B
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ylated in Thr18 (Fig. 2C), and thus transcriptionally active which
can induce two p53-dependent genes, p21 [36] and DRAM gene
expression [37]. The induction of p21, a cell cycle inhibitor, was
confirmed in an immunoblot (Fig. 2C). The DRAM expression is
indeed induced by leptomycin in the WS1 cell line (Fig. 2D), but in
this situation it does no degrade VRK1 (Fig. 2C) due to their
nuclear localization. This result indicates that DRAM is
participating in the removal of the cytosolic pool of VRK1.
The instability of VRK1 is not due to loss of its activity, since
kinase-dead VRK1(K179E) is equally degraded by increased levels
of p53 or DRAM (Fig. S1C).
A subpopulation of DRAM colocalizes in Golgi apparatus
and endosome vesicles with VRK1
VRK1 is mostly nuclear, but there is always a subpopulation
that is cycling in the cytosol [38] and can be detected in cytosolic
vesicles, mainly in the Golgi apparatus [39], and can be detected
with a specific antibody [38]. This VRK1 subpopulation enters a
degradation pathway that ends in the lysosome [23]. Overex-
pressed DRAM was detected in lysosomes colocalizing with
cathepsin D [40]. To ascertain if cytosolic VRK1 could also be
detected in a common intracellular compartment with DRAM
protein, the subcelular location of DRAM was determined in
combination with several components of the Golgi-endosome-
lysosome vesicular traffic that were used as markers. VRK1 is
already known to be present in Golgi, colocalizing with giantin
[38,39]. DRAM protein was partially detected colocalizing with
both VRK1 and giantin in cytosolic vesicles (Fig. 3A, B). DRAM
also colocalized with GM130 (Fig. 3C), a marker of cis-Golgi; with
EEA1, a marker for early endosome vesicles (Fig. 3D) and with
LAMP2, a lysosomal marker (Fig. 3E). DRAM was detected in all
these compartments suggesting that DRAM localization is more
widely expressed than previously reported [30], and is not limited
to lysosomes, but also colocalize with the Golgi as part of the
degradation pathway of endosomal-lysosomal intracellular traffic.
DRAM might be a component of a specific subtype of
endosomal vesicles required for lysosomal fusion, or represent a
ligand for stable proteins that have to be removed. Therefore it
was determined if a direct interaction between VRK1 and DRAM
could be detected in reciprocal immunoprecipitation experiments.
No direct interaction was detected (not shown), thus suggesting
that DRAM is more likely to be a marker of the vesicle subtype
and which is necessary for degradation. TSG101 is a protein
implicated in endosomal traffic related to receptor recycling
[31,32,41], therefore it was tested if TSG101 could intracellularly
colocalize with DRAM (Fig. 3F). TSG101 and DRAM do not
colocalize in intracellular vesicles indicating that they are markers
for different subpopulations of endosomal vesicles. It was also
determined the localization of VRK1 and TSG101 (Fig. 3G); these
two proteins do not colocalize, but in the presence of low level of
endogenous DRAM, TSG101 is more dispersed and some is
located in the plasma membrane, its natural location before it is
internalized.
VRK1 downregulation after p53 stabilization by DNA
damage follows DRAM accumulation
It was previously reported that VRK1 downregulation induced
by p53 required de novo gene expression of an inducible gene that
targets VRK1 for lysosomal degradation [23]. The contribution of
ubiquitin ligases to VRK1 degradation has been rule out [23].
VRK1 is not ubiquitylated and VRK1 degradation is insensitive to
mdm2 and to proteasome inhibitors, and VRK1 is also degraded
in mdm22/2 cells [23]. One likely candidate is DRAM, a p53-
induced gene [30], and the results above suggest that indeed this
might be the case. In order to determine the potential relation
between DRAM, VRK1 downregulation and p53 levels, a
temporal assay of sequential changes in VRK1, p53 and DRAM
protein levels was performed in WS1 cells after irradiation with
UV-C light (254 nm). Normal human WS1 fibroblast cell line was
treated with UV (10 J/m2) and the level of different proteins
determined at different time points. Shortly after irradiation
there is an accumulation of VRK1 and p53, followed by an
accumulation of DRAM and Hdm2. As p53 increases so does the
level of DRAM protein, which is followed by a reduction of VRK1
protein (Fig. 4A). This reduction in VRK1 is accompanied by a
decrease in p53 phosphorylated in Thr18, and thus also the
initiation of a reduction in total p53 protein due to its accessibility
to the accumulated Hdm2 (Fig. 4A). The quantification of the blot
is shown at the bottom (Fig. 4A). In this system the accumulation
of DRAM protein (Fig. 4A) was a consequence of the activation of
DRAM gene transcription as determined by qRT-PCR at different
times after UV treatment (Fig. 4B).
Since p53 is stabilized by phosphorylation, we tested if
downregulation of VRK1 would also prevent accumulation of
p53 in response to UV treatment. Control cells accumulated p53
in response to UV, but the knockdown of VRK1 prevented the
accumulation of p53, and its Thr18 phosphorylation induced by
UV light with respect to the siControl and non-transfected control
cells (Fig. 4C).
Knockdown of DRAM and Beclin-1 prevents VRK1
downregulation induced by UV light
To confirm the implication of DRAM in VRK1 downregula-
tion induced by UV light, the level of endogenous DRAM was
knocked-down by specific siRNA in WS1 fibroblasts. VRK1
protein level was higher in response to UV when DRAM was
knocked-down (Fig. 5A). SiDRAM-01 was very effective in
downregulating DRAM mRNA levels, while DRAM expression
was induced in non-transfected or in siControl cells (Fig. 5B).
These results confirmed the role of DRAM in UV-light induced
downregulation of VRK1.
Beclin-1 is a protein that is required for autophagy [42,43]. To
further confirm that VRK1 degradation induced by UV is indeed
Figure 1. Effect of p53 on the transcription of endogenous DRAM gene. (A) Determination of the optimal dose of UV light that induces p53
stabilization and its phosphorylation in Thr18 in the WS1 cell line. To the right is shown the quantification of p53 and p53 phosphorylated in Thr18 as
a function of the UV dose. (B) Different types of DNA damage induce endogenous p53 accumulation, and VRK1 downregulation in WS1 fibroblasts
(p53+/+) determined by western blot (top). DNA damage also induces DRAM accumulation detected by qRT-PCR in human WS1 fibroblasts. The DNA
damage agents used were doxorubicin, etoposide, ionizing radiation and UV-C light (254 nm). (C) H1299 (p532/2) cells transfected with increasing
amounts of plasmid pCB6+p53 and expression of DRAM was determined by qRT-PCR. Values are the mean of three experiments with standard
deviation. Same amount of DNA was used in all transfections that were completed with empty vector as necessary. (D) H1299 (p532/2) were
transfected with the indicated plasmids pCB6+p53 (wt), pCMV-p53
R175H, pCMV-p53
R248W and pCMV-p53
R273H, and the effect on the expression of
endogenous DRAM gene expression was determined by qRT-PCR. In the immunoblots (IB) at the bottom is shown the correct expression of the
different p53 proteins, wild-type or mutants.
doi:10.1371/journal.pone.0017320.g001
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was also determined. The knock-down of Beclin1 prevented UV
induced degradation of VRK1, an effect that was also observed by
either addition of leptomycin B or siDRAM, all of which
prevented VRK1 protein degradation (Fig. 5A). These results
confirmed that VRK1 degradation requires nuclear export to
enter the autophagic degradation process. Leptomycin B is known
to induce p21 to block cell cycle progression and DRAM in the
autophagic pathway, both as a result of the nuclear accumulation
of p53 [36,37]. Beclin-1 knockdown by specific siRNA is effective
and was not affected by UV irradiation (Fig. S2). In addition to the
activation of p53 and the autophagic route in response to UV
Figure 2. Dose dependent effect of DRAM on VRK1, and TSG101 protein levels. The variation in levels of VRK1 (A), and the control
endosomal protein TSG101 implicated endocytic recycling of plasma membrane receptors and caveolin (B) were determined in response to
increasing levels of DRAM. H1299 (p532/2) cells were transfected with a fixed amount of VRK1 and TSG101 plasmids, and varying concentrations of
DRAM. Plasmid pCDNA3-DRAM-Myc-His [30], plasmid pCEFL-HA-VRK1 [18,23] and plasmid pHA-TSG101 [65] were used. To the bottom is shown the
quantification of corresponding immunoblots in the linear response range. VRK1 and TSG101 proteins were detected with an anti HA antibody.
DRAM was detected with an anti myc antibody. C. The block of nuclear export by leptomycin B in WS1 cell line prevented degradation of VRK1 even
though there is an accumulation p53, which is also phosphorylated in Thr18 and induces DRAM gene expression. D. Accumulation of p53 by
leptomycin B induces DRAM gene expression in WS1 cells as determined by quantitative qRT-PCR.
doi:10.1371/journal.pone.0017320.g002
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PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e17320Figure 3. Subcellular localization of DRAM. (A–E) Colocalization of DRAM in different Golgi-endosome-lysosome compartments. (F) TSG101 and
DRAM do not colocalize in endoplasmic vesicles. (G) TSG101 and VRK1 colocalize in different locations in the absence of DRAM. In these experiments,
H1299 cells were transfected with plasmid pCDNA3-DRAM-Myc-His and plated on 10-cm
2 dishes (5610
5) containing 1-cm-diameter sterile glass
coverslips. The coverslips were stained twenty-four hours after DRAM transfection with specific antibodies for the endogenous proteins: VRK1 (1F6),
giantin, GM130, EEA1 and LAMP2. DRAM was detected with an anti-myc epitope antibody. TSG101 was detected with a polyclonal antibody.
doi:10.1371/journal.pone.0017320.g003
DRAM Is Required for VRK1 Downregulation
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SQSTM1 and LC3B, two proteins known to be degraded by
autophagy [44,45,46], and which were used a positive controls for
autophagy in our system. Both, LC3 and p62/SQSTM1 (Fig. 5C)
behave in a similar way as VRK1 (Fig. 5A) in response to DNA
damage by UV light.
Discussion
The downregulation of cellular proteins induced by p53 is a
phenomenon that is lately acquiring relevance due to the role that
p53 plays in several processes such as cell cycle, apoptosis and
autophagy. However, the particular context that makes p53 to
induce one biological response or another is not completely
understood, although some of the components have already being
identified. The determination of a specific response is likely to be
dependent on protein levels, and the degree of phosphorylation of
the individual components that can regulate interactions with co-
transcriptional activators, which affect the selection of the genes
regulated by p53. Among p53-regulated genes is DRAM [30] that
is implicated in the removal of long-lived proteins [26]. One of
these proteins is VRK1 that has a very large half-life [13].
Kinases that stabilize p53 are likely candidates to be selectively
removed, or inactivated, in order to permit p53 dephosphoryla-
tion; making it accessible to Hdm2 and susceptible to ubiquitin-
mediated downregulation, and thus generating fluctuations of their
Figure 4. Sequential changes in VRK1, p53 and DRAM protein levels induced by UV in WS1 human fibroblasts. (A) Levels of the three
proteins VRK1, p53 and DRAM after treating human fibroblasts WS1 with UV light. The relative level of each protein was quantified and represented in
the graph at the bottom. (B) Quantification of DRAM RNA levels by qRT-PCR at different time points following treatment with UV light. Mean of three
independents experiments with standard deviation. (C). Knockdown of VRK1 (siV), but not controls (siC and NTC), prevented the accumulation of p53
and its phosphorylation in Thr18 in response to UV irradiation. Knock-down siRNA transfections were performed 96 hours before the start of UV
treatment. Cell lysates were prepared 12 hours after irradiation.
doi:10.1371/journal.pone.0017320.g004
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loops [10]. In this context, the induction by p53 of DRAM
protein, which contributes to the removal of VRK1 protein, is
consistent with this picture (Fig. 6). Because VRK1 is a stabilizer
and activator of p53 transcriptional activity, the downregulation of
p53 levels requires the removal of its stabilizer, VRK1, otherwise
the p53 phosphorylated in Thr18 cannot interact with Hdm2 [9]
and will not be degraded. Thus, it is likely that the regulation of
p53 is accompanied by an additional mechanism needed to
downregulate its stabilizer kinase, VRK1, by a p53 dependent
gene, as it is the case of DRAM. The double autoregulatory loop of
VRK1 and p53, in which DRAM and Hdm2 participate is
represented in Fig. 6. Briefly, the activation by phosphorylation of
p53 in response to UV light induces an activation of gene
Figure 5. Knock-down of DRAM and Beclin-1 (BECN1), and addition of leptomycin B prevented downregulation of VRK1 induced by
UV light. (A) Human fibroblast WS1 cells were transfected with siControl, siDRAM-01, siBECN1-smart pool, or treated with leptomycin B. After that,
these cells were irradiated with UV-C light and the protein levels determined at different time points. The changes in levels of VRK1 protein were
detected with the 1B5 mAb. The quantification of the blots is shown in the graph at the right. (B). The effectiveness of the DRAM knock-down was
determined by qRT-PCR and the result shown in the bar graph at the bottom, and siBECN1 by western blot (Fig. S2). Knock-down siRNA transfections
were performed 48 hours, and addition of leptomycin B was 12 hours, before the start of UV treatment. (C) P62/SQSTM1 and LC3B are proteins
degraded by autophagy. P62/SQSTM1 and LC3B proteins are also degraded in response to UV light, following a transient accumulation in
autophagosomes after induction of damage [60,61].
doi:10.1371/journal.pone.0017320.g005
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transcription will result in either cell death or permanent cell cycle
arrest. Therefore mechanisms to make transient this arrest are
necessary at later times to prevent potentially deleterious effects. It
is well known the autoregulation mediated by Hdm2 targeting p53
for degradation in the proteasome [49], and it has been detected in
the case of other activating kinases such as ATM [50] and CHK2
[51], but this action requires a p53 induction of phosphatases, such
as PPM1D [52] and Wip1 [51]. To these effects it has to be added
the removal of VRK1 by DRAM. DRAM is also induced by UV
light [37], an effect mediated by p53. These autoregulatory
mechanisms can be partly implicated in the cellular fluctuations of
p53 levels [53,54], and should be integrated in the complex
regulation of p53 [10].
The role of DRAM in downregulation of different proteins is
not yet known, but its structure suggests it is a small hydrophobic
protein with six transmembrane domains [30], and it is very likely
that DRAM is a regulated component in the process of fusion
between lysosomes and some endosome vesicles. But since not all
endosomal markers are degraded it means that the endosome
population is heterogeneous, some are fused to the lysosomes,
those containing VRK1, and others not, like the ones containing
TSG101 which are implicated in vesicle recycling for downreg-
ulation of plasma membrane receptors [32,41,55]. DRAM might
play two potentially different roles. One is to be the ligand for
specific stable proteins that are removed by autophagy, which we
consider unlikely since we could not detect a direct interaction
between VRK1 and DRAM. Alternatively, DRAM might
function as a marker of a subpopulation of vesicles destined for
fusion to lysosomes and thus identified endosomal vesicles; in this
context DRAM might be a receptor for a lysosomal protein
required for vesicle fusion. The small size and the six transmem-
brane domains of DRAM suggests that most of it is not exposed,
that is more logical to think of it as interacting with an unknown
protein with lysosomes or an intermediate vesicle in the
autophagic pathway, rather than a receptor for specific proteins
destined for degradation in this pathway. Downregulation of
DRAM in human cancer, like in melanomas [56], not only
permits the survival of stress damaged cells, but also contributes to
the maintenance of proteins which promote progression of the cell
cycle, as is the case of VRK1, implicated in early G0/G1 [13]
resulting in a mitotic delay [57], and required for Golgi
fragmentation in mitosis [39], but which is likely to have additional
roles along the cell cycle. In cells resistant to carboplatin there is an
increase in VRK1 levels, probably reflecting a defective p53
response, and also favoring cell survival [58].
The accumulation of VRK1 is likely to drive to progression of
cell division and thus expand a cell population that is mutated and
implicated in tumor development. In tumors there are two possible
situations resulting in VRK1 accumulation. Tumors with
mutations in p53 will not induce DRAM and thus result in
VRK1 accumulation. This correlation has already been detected
in lung carcinomas [25] and in breast cancer (unpublished results).
Alternatively, if there were tumors with DRAM inactivating
mutations [40], they should also accumulate VRK1, but this
possibility has not yet been studied. It is important to note that in
tumors with p53 mutations, which are unable to induce DRAM
expression, there would be an alteration in the regulation of
autophagy, and this defective response can contribute to genetic
instability [59]. In addition, it has been reported that apoptosis
and autophagy induced in response to stress and mediated by JNK
activates DRAM expression [60,61]. Interestingly, VRK1 phos-
phorylates c-Jun in the same residues, Ser63 and Ser73, as JNK
and their phosphorylation has an additive effect [62], which
suggests that cells might be responding to stress in two different
ways that perhaps can cooperate in the regulation of the initial
stress response. The removal of VRK1 could be considered as part
of a rescue mechanism [63], and defective induction of autophagy
can contribute to genomic instability, as shown in a breast cancer
model [64]. Therefore, there must be a fine regulatory balance
among different p53 mediated responses, such as the equilibrium
between cell-cycle arrest, apoptosis and autophagy, for which
there has to be an underlying equilibrium between regulation of
protein accumulation and degradation to protect cells from
accumulating DNA damage, once it has been repaired. These
regulatory loops modulate the balance between cell cycle
progression and cell death by apoptosis or autophagy in DNA
damage responses.
Materials and Methods
Cell lines and tissue culture
The human fibroblast WS1 cell line (CRL-1502) was obtained
from the ATCC (Manassas, VA). Cells were grown in DMEM
with 10% fetal calf serum and supplemented with antibiotics and
glutamine. H1299 lung carcinoma cell line was grown in RPMI
with 10% fetal calf serum and supplemented with antibiotics and
glutamine (CRL-5803, ATCC) [13,23,24]. Cells plated on
100 mm dishes were treated with UV-C (254 nm) light in a
Stratalinker. The real value of the UV dose delivered in each the
experiment was confirmed by direct internal measurement with a
radiometer Spectroline XS-254nm-UVC (Spectronics Corpora-
tion, Westbury, NY). Alternatively cells were treated with different
drugs (Doxorubicin 0.5 mM, Etoposide 20 mM, Leptomycin B
0.2 nM [36] or IR (9 Gy) for WS1, or transfected for H1299.
Plasmids and transfections
Plasmid pCB6+p53 were from K. Vousden (The Beatson
Institute for Cancer Research, Glasgow, Scotland, UK) and
pCMV-p53
R175H, pCMV-p53
R248W and pCMV-p53
R273H were
from B. Vogelstein (John Hopkins University). Plasmid pCDNA3-
DRAM-Myc-His was a gift from K.M. Ryan [30]. VRK1,
VRK2A and VRK2B were expressed from plasmids pCEFL-HA-
Figure 6. Model of the autoregulatory VRK1-p53-Hdm2-DRAM
loop. Several types of DNA damage mechanisms can induce VRK1,
stabilizing and activating p53-dependent transcription (black line).
Among the p53-induced genes, Hdm2 promotes p53 degradation via
ubiquitylation (blue line), and DRAM induces VRK1 degradation in the
lysosome (red line). VRK1 and DRAM are in the same late endosomal
vesicle that fuses to lysosomes, but do not interact directly. PP:
unknown phosphatase.
doi:10.1371/journal.pone.0017320.g006
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and pCEFL-HA-VRK2B [34]. TSG101 was expressed from
plasmid pHA-TSG101 [65]. In all transfection experiments the
total amount of DNA was always kept constant with empty vector.
Knock-down of VRK1, DRAM, and Beclin-1
Synthetic SMART specific siRNA duplexes were purchased
from Dharmacon RNA Technologies (Lafayette, CO). The
targeted sequence for human DRAM (Accession number: NM_
018370) was knock-down using siRNA (siDRAM-01 from
Dharmacon RNAi Technologies); sense sequence: 5- CCACA-
GAAAUCAAUGGUGAUU; antisense sequence: 59-P-UCACC-
AUUGAUUUCUGUGGUU. The targeted sequence for VRK1
(Accession number: NM_003384) was CAAGGAACCTGGTG-
TTGAA (duplex siVRK1-2) from Dharmacon. Beclin-1 was
knocked down with siRNA-BECN1 on-Target plus SMART pool
from Dharmacon. Functional siCONTROL non-targeting siRNA
pool from Dharmacon was used as a negative control and
fluorescently labeled siGLO Lamin A/C siRNA for transfection
efficiency. Transfections of siRNA duplexes at 100–200 nM final
concentration were carried out using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) following manufacturer instructions.
After transfection, cells were processed for western blot or qRT-
PCR as previously reported [13,23].
qRT-PCR
WS1 cells were washed in ice-cold PBS. Total RNA was
extracted using the ‘‘RNAeasy extraction kit’’ from Quiagen
(Hilden, Germany). RNA was analyzed and quantified using a
Bioanalyzer 2100 nano-lab chip from Agilent Technologies
(Bo ¨blingen, Germany). 100 ng of total RNA were used in a one-
step reverse transcription real-time PCR amplification reaction
using the ‘‘Quantitec SYBR Green RT-PCR kit’’ from Qiagen in
an iCycler (BioRad, Hercules, CA). The reaction was analyzed
with iCycler software (BioRad) and PCR products were resolved in
a 1.5% agarose ethidium-bromide gel. The following forward (F)
and reverse (R) primers were used for specific human DRAM
message detection. Human DRAM (DRAM-F: 59- TCAAATAT-
CACCATTGATTTCTGT -39; DRAM-R: 59- GCCACATACG-
GATGGTCATCTCTG -39) [30], human VRK1 (VRK1-F: 59-
CCAACGAGCTGCAAAACC-39; VRK1-R: 59-TGTCATGTA-
GACCAGACCCCC-39) [13], and GAPDH amplification was
used as internal control (GAPDH-F: 59-GGTCTTACTCCTTG-
GAGGCCATGT-39; GAPDH-R: 59-ACCTAACTACATGGT-
TTACATGTT-39) [13].
Antibodies and immunoblots analysis
Cell extracts were prepared by homogenization in lysis buffer
(Tris-HCl 50 mM pH 8, 200 mM NaCl, 5 mM EDTA, 1%Triton
X-100 and protease and phosphatase inhibitors), and 40
micrograms were loaded for each sample in a 10% SDS-PAGE
and transferred to Immobilon-P membrane (Millipore, Billerica,
MA); membranes were processed for western blot, detection with a
chemiluminescence ECL kit (GE Healthcare) that were quantified
in the linear response range using an FX Personal Imager
(BioRad) as previously reported [24].
Human VRK1 protein was detected with the 1F6 or 1B5
monoclonal antibodies [38]. The p53 protein was detected with a
mixture of DO1 antibody from Santa Cruz Biotechnology (Santa
Cruz, CA) and Pab1801 (Santa Cruz, CA) used at 1:500 and 1:1000
respectively. To detect endogenous p53 phosphorylated in Thr18
was detected with a rabbit polyclonal antibody from Cell Signaling
Technology [18]. DRAM was detected with an antibody from
ABCAM (Cambridge, UK) or myc epitope (Anti-Myc Tag
Polyclonal Antibody, Upstate).VRK2A/B and TSG101 were
detected with an anti HA epitope monoclonal antibody (Covance,
Emeryville, CA). Endogenous TSG101 was detected with a rabbit
polyclonal antibody [65]. The following antibodies were used: EEA1
detected with mAb 4/EEA1, and GM130 with mAb 35/GM130
from BD Transduction Laboratories (San Jose ´, CA). Giantin
detected with polyclonal PRB-114C from Covance. LAMP2
detected with mAb H4B4, Beclin-1 was detected with a polyclonal
antibody (sc-11427), p21 with mAb F-5 (sc-6246), and p62/
SQSTM1 was detected with a monoclonal antibody (sc-28359), all
from Santa Cruz Biotechnology (Santa Cruz, CA). LC3B was
detected with a polyclonal antibody from Cell Signaling. Caveolin
was detected with a rabbitpolyclonal antibody from BD Biosciences.
Hdm2 was detected with a monoclonal mouse Anti-Human MDM2
protein(Clone SMP14)fromDAKO. Alltheantibodies were usedat
a 1:1000 dilution for western blots, and at1:100 for immunofluores-
cence. b-actin was detected with monoclonal antibody (Clone AC-
15) from Sigma (St. Louis, MO) at a 1:5000 dilution.
Immunofluorescence and confocal microscopy
H1299 cells (5610
5) were plated on 10-cm
2 dishes containing 1-
cm-diameter sterile glass cover slips. The coverslips were stained
twenty-four hours after DRAM transfection with specific antibod-
ies for the endogenous and transfected proteins. Cells were washed
three times with PBS and then fixed in 4% paraformaldehyde in
PBS for 30 min at room temperature. After fixation the cells were
permeabilized in cold PBS containing 0.2% Triton X-100 for
30 min and then treated with glycine 10 mM for 10 min at room
temperature. Staining with antibodies was as previously reported
[18,39]. Subcelular localization was analyzed with a Zeiss LSM
510 confocal microscope.
Supporting Information
Figure S1 Dose dependent effect DRAM on levels of
VRK2A (A), VRK2B (B). H1299 cells were transfected with a
fixed amount of VRK plasmids, and varying concentrations of
DRAM. Plasmid pCDNA3-DRAM-Myc-His (Crighton et al.,
2006). Plasmids pCEFL-HA-VRK2A o pCEFL-HA-VRK2B has
been previously reported (Blanco, et al. 2006). To the bottom is
shown the quantification of corresponding immunoblots. VRK
proteins were detected with an anti HA antibody. DRAM was
detected with an anti myc antibody. (C). Overexpression of p53
(left) or DRAM (right) induce downregulation of kinase-dead
VRK1(K179E).
(TIF)
Figure S2 DNA damage does not affect the effectiveness
of BECN1 knockdown. The knockdown of beclin-1 using
siBECN1 is not affected by the time after induction of DNA
damage by UV light. The experiment was performed in WS1 cells.
The antibodies used in the immunoblots are described in the
Materials and Methods section.
(TIF)
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